RxSight

RXST

Market cap $488M

ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City.

RxSight, Inc. ( RXST ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Oliver Moravcevic Ronald Kurtz - Co-President, CEO & Director Shelley Thunen - Co-President & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division David Saxon - Needham & Company, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Patrick Wood - Morgan Stanley, Research Division K. Gong - JPMorgan Chase & Co, Research Division Adam Maeder - Piper Sandler & Co., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, everyone.

RxSight, Inc. (RXST) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago.

ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2025.

ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced it will be featured in multiple Live Learning Sessions at Booth #2931 during the American Academy of Ophthalmology Annual Meeting (AAO 2025), taking place October 18–20 at the Orange County Convention Center in Orlando, Fla.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST).

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.

NEW YORK--(BUSINESS WIRE)---- $RXST #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.